Table 1.
Baseline characteristics of study population (n = 14).
| Parameters | No. (%) |
|---|---|
| Age, years, median (range) | 59.5 (40-68) |
| Gender, n (%) | |
| Male | 12 (85.7) |
| Female | 2 (14.3) |
| ECOG* | |
| 0 | 11 (78.6) |
| 1 | 3 (21.4) |
| Liver cirrhosis, n (%) | |
| Yes | 14 (100) |
| No | 0 |
| Child-Pugh score | |
| A (5-6) | 12 (85.7) |
| B (7-9) | 2 (14.3) |
| Etiology of HCC, n (%) | |
| Hepatitis B | 10 (71.4) |
| Hepatitis C | 1 (7.2) |
| No | 3 (21.4) |
| Differentiated degree | |
| High | 3 (21.4) |
| Median | 7 (50.0) |
| Poor | 2 (14.3) |
| No | 2 (14.3) |
| BCLC* stage | |
| B | 2 (14.3) |
| C | 12 (85.7) |
| Prior therapies | |
| Surgery | 4 (28.6) |
| Ablation | 14 (100) |
| TACE* | 11 (78.6) |
| Sorafenib/Lenvatinib | 7 (50.0) |
| APF* level (ug/ml) | |
| < 20 | 1 (7.1) |
| ≥ 20 | 13 (92.9) |
*ECOG, Eastern Cooperative Oncology Group; HCC, hepatocellular carcinoma; BCLC, Barcelona Clinic Liver Cancer; TACE, transarterial chemoembolization; AFP, alpha fetoprotein.